Galectin-1 and -3 in high amounts inhibit angiogenic properties of human retinal microvascular endothelial cells in vitro

PLoS One. 2022 Mar 23;17(3):e0265805. doi: 10.1371/journal.pone.0265805. eCollection 2022.

Abstract

Purpose: Galectin-1 and -3 are β-galactoside binding lectins with varying effects on angiogenesis and apoptosis. Since in retinal pigment epithelial cells high amounts of human recombinant galectin (hr-GAL)1 and 3 inhibit cell adhesion, migration and proliferation, we investigated if hr-GAL1 and 3 have homologous effects on human retinal microvascular endothelial cells (HRMEC) in vitro.

Methods: To investigate the effect of galectin-1 and -3 on HRMEC, proliferation, apoptosis and viability were analyzed after incubation with 30, 60 and 120 μg/ml hr-GAL1 or 3 by BrdU-ELISA, histone-DNA complex ELISA, live/dead staining and the WST-1 assay, respectively. Further on, a cell adhesion as well as tube formation assay were performed on galectin-treated HRMEC. Migration was investigated by the scratch migration assay and time-lapse microscopy. In addition, immunohistochemical staining on HRMEC for β-catenin, galectin-1 and -3 were performed and β-catenin expression was investigated by western blot analysis.

Results: Incubation with hr-GAL1 or 3 lead to a decrease in proliferation, migration, adhesion and tube formation of HRMEC compared to the untreated controls. No toxic effects of hr-GAL1 and 3 on HRMEC were detected. Intriguingly, after treatment of HRMEC with hr-GAL1 or 3, an activation of the proangiogenic Wnt/β-catenin signaling pathway was observed. However, incubation of HRMEC with hr-GAL1 or 3 drew intracellular galectin-1 and -3 out of the cells, respectively.

Conclusion: Exogenously added hr-GAL1 or 3 inhibit angiogenic properties of HRMEC in vitro, an effect that might be mediated via a loss of intracellular endogenous galectins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Endothelial Cells / metabolism
  • Galectin 1* / metabolism
  • Galectin 1* / pharmacology
  • Galectins
  • Humans
  • Neovascularization, Pathologic / genetics
  • beta Catenin* / metabolism

Substances

  • Galectin 1
  • Galectins
  • beta Catenin

Grants and funding

AO; OH 214/4-3; Deutsche Forschungsgemeinschaft; https://www.dfg.de; The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. CP; PR 1248/2-3; Deutsche Forschungsgemeinschaft; https://www.dfg.de; The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.